Article
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.
Investigational new drugs - 1 Dec 2011
Garrett Christopher R, Coppola Domenico, Wenham Robert M, Cubitt Christopher L, Neuger Anthony M, Frost Timothy J, Lush Richard M, Sullivan Daniel M, Cheng Jin Q, Sebti Saïd M
Abstract excerpt
PURPOSE: Triciribine phosphate is a potent, small-molecule inhibitor of activation of all three isoforms of AKT in vitro. AKT is an intracellular protein that, when activated, leads to cellular division; it is dysregulated in a large number of malignancies, and constitutively activating AKT mutations are present in a minority of cancers. PATIENTS AND METHODS: In this phase I study triciribine phosphate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.